TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06609083

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 30mg
Description: High dose of THC (30 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 30mg
Description: High dose of THC (30 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5mg
Description: Low dose of THC (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 5mg
Description: Low dose of THC (5 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 0mg
Description: Placebo dose of THC (0 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THC 0mg
Description: Placebo dose of THC (0 mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette Full Nicotine
Description: Full nicotine cigarette

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette Full Nicotine
Description: Full nicotine cigarette

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette Reduced Nicotine
Description: Reduced nicotine cigarette

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cigarette Reduced Nicotine
Description: Reduced nicotine cigarette
Study: NCT06609538

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Receives standard preoperative instructions and propofol or ketamine infusion.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Control Group
Description: Receives standard preoperative instructions and propofol or ketamine infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suggestion Group
Description: Receives positive preoperative suggestions and propofol or ketamine infusion.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Suggestion Group
Description: Receives positive preoperative suggestions and propofol or ketamine infusion.
Study: NCT06609616

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Motion Sensor
Description: The motion sensor is the 10-axis Bluetooth Gyro Inclinometer by Wit Motion and is marketed for rehabilitation exercises, workplace injury prevention, patient care, and healthy shortrange wireless motion measurements.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Incentive Spirometer
Description: a device that measures the volume of the air inhaled into the lungs during inspiration.
Study: NCT05344612

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: CT Coronary Angiography
Description: Upfront ct-coronary angiography
Study: NCT06168474

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Simplified layered consent form
Description: The simplified consent form includes all essential elements of trial consent including an explanation of the trial procedures, data and sample collection, and follow-up information. The form also outlines important ethical considerations for patients, such as confidentiality, regulatory and safety requirements, the ability to drop out, and the necessary process and contact numbers for grievances or feedback. In addition to the text, the form includes links to additional written information and videos that can be accessed on top of the simplified informed consent form (i.e., the additional layers in the layered consent process). These materials are hosted on the main SNAP trial website (https://www.snaptrial.com.au/patients) and are available in English and French. Participants will be able to access these directly through embedded hyperlinks using provided electronic tablets.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Full-length consent form
Description: The full-length informed consent form contains all information upfront. Links to additional information will not be provided on the form but are freely available on the Internet should the participant wish to access them.
Study: NCT05427175

Intervention type: RADIATION
Group type: ACTIVE_COMPARATOR
Intervention: Narrowband ultraviolet B
Description: Patients will receive 8 sessions of NB-UVB per month for 3 successive months
Study: NCT06611293

Intervention type: DIAGNOSTIC_TEST
Intervention: Breath test
Description: Participants will perform breath testing in Primary care followed by Secondary care on Day 1. At each location, participants will be asked to perform three breath tests (15 minutes apart). The environmental air will also be sampled.~This entire process will be repeated in the reverse order (i.e. breath testing in Secondary care followed by Primary care on Day 2).~Participants will be asked to maintain a clear fluid diet for a minimum of six hours prior to breath collection on both Day 1 and Day 2 of sampling.
Study: NCT06669754

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deucrictibant
Description: Deucrictibant 40mg extended-release tablet for once daily oral use

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo
Study: NCT06670534

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003142 tablets
Description: JMKX003142 tablets for experimental groups.Take the JMKX003142 tablets（on empty stomach） once daily for seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003142 tablets
Description: JMKX003142 tablets for experimental groups.Take the JMKX003142 tablets（on empty stomach） once daily for seven days.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JMKX003142 tablets
Description: JMKX003142 tablets for experimental groups.Take the JMKX003142 tablets（on empty stomach） once daily for seven days.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Torasemide tablets
Description: Torasemide tablets for active comparator group.Take the torasemide tablets once daily for seven days.
Study: NCT05939336

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Mannooligosaccharides yeast extract
Description: 15 g per day of mannooligosaccharide yeast extract.
Study: NCT05427175

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Patients will receive 25 mg/1ml of methotrexate vial per week for 3 successive months
Study: NCT05374434

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional irrigation
Description: The participant will be treated by manual irrigation with sodium hypochlorite NaOCl.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Inertial cavitation
Description: The participant will be treated by inertial cavitation-generating device, that generates hydraulic cavitation to clean root canals deeper and more effectively than other existing systems.
Study: NCT06506786

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden-fresh Produce
Description: Participants are asked to consume the USDA-recommended amounts of fruits and vegetables harvested from their gardens.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Garden-fresh Produce
Description: Participants are asked to consume the USDA-recommended amounts of fruits and vegetables harvested from their gardens.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supermarket Produce
Description: Participants are asked to consume the USDA-recommended amounts of fruits and vegetables purchased from a supermarket.

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supermarket Produce
Description: Participants are asked to consume the USDA-recommended amounts of fruits and vegetables purchased from a supermarket.
Study: NCT05496062

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F&P Toffee Nasal and Toffee Nasal Pillows Masks
Description: F\&P Toffee Nasal and Toffee Nasal Pillows Masks are intended to be used within the traditional PAP therapy system and are designed to facilitate equivalent PAP therapeutic efficacy as defined by standard practice.
Study: NCT06612203

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Debio 0123 and Sacituzumab govitecan
Description: Debio 0123 will be administered orally during 6 days of each 21-day cycle in combination with 10 mg/kg of Sacituzumab govitecan administered intravenously on D1 and D8 of each 21-day cycle until documented disease progression, death, unacceptable toxicity, or discontinuation from the study treatment for any other reason, whichever occurs first.
Study: NCT05998902

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Trophic enteral feeding combined with supplemental parenteral nutrition
Description: The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Patients will receive the trophic enteral feeding with a caloric target of 500kcal/d (20-35ml/h), and the remaining calories are supplemented by parenteral nutrition. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Full enteral feeding
Description: The caloric goal of the first day is one-third of caloric requirements, the second day is half of caloric requirements, the third day is 70-100% and sustained for 1 week. Protein requirements are calculated at 1.2 to 1.5 g per kilogram of body weight per day. Enteral nutrition is given through nasogastric tube or nasointestinal tube.
Study: NCT05432804

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Biospecimen Collection
Description: Undergo blood sample collection

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Biospecimen Collection
Description: Undergo blood sample collection
Study: NCT06379412

Intervention type: OTHER
Intervention: observational study, no intervention
Description: observational study, no intervention

Intervention type: OTHER
Intervention: observational study, no intervention
Description: observational study, no intervention

Intervention type: OTHER
Intervention: observational study, no intervention
Description: observational study, no intervention

Intervention type: OTHER
Intervention: observational study, no intervention
Description: observational study, no intervention
Study: NCT05821192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 by IV infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: 1 g/m2 on Days 1 by IV infusion once every 3 weeks
Study: NCT05251974

Intervention type: DIAGNOSTIC_TEST
Intervention: Quest beta blocker assay
Description: Blood assay to detect presence of beta blocker medications

Intervention type: DIAGNOSTIC_TEST
Intervention: Quest beta blocker assay
Description: Blood assay to detect presence of beta blocker medications
Study: NCT05015608

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Savolitinib + Osimertinib
Description: Subjects will receive Savolitinib orally once per day (QD) + Osimertinib orally QD,21day cycles (every 3 weeks) until disease progression, death, adverse event (AE) leading to discontinuation or withdrawal of consent.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pemetrexed + Cisplatin /Carboplatin
Description: Pemetrexed combined with platinumon on Day 1 of 21day cycles (every 3 weeks)
Study: NCT05821192

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Description: 40 mg on Days 1 to 4 of each 3-week cycle by IV infusion

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin
Description: 75 mg/m2 on Days 1 by IV infusion once every 3 weeks

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PD-1 monoclonal antibody
Description: 200mg on Days 2 by IV infusion once every 3 weeks
Study: NCT06284174

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution; chlorhexidine gluconate
Description: Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Povidone-iodine solution; chlorhexidine gluconate
Description: Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Povidone-iodine solution; chlorhexidine gluconate
Description: Before wound closure, each group will undergo different irrigation solutions for soaking the wound for three minutes followed by rinsing with copious saline.
Study: NCT05965154

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carrilizumab, bevacizumab,capecitabine
Description: 1. Carrilizumab: 200mg/ cycle, three weeks as a treatment cycle, the first day of each cycle, intravenous drip;~2. Bevacizumab: 7.5mg/kg, intravenous infusion on the first day of each cycle, every 3 weeks for 1 cycle (Q3W);~3. Capecitabine: 1250mg/m2, three weeks as a treatment cycle, oral twice a day (once in the morning and once in the evening; Stop the drug for 1 week after 2 weeks of treatment.
Study: NCT06497413

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Transcranial Photobiomodulation
Description: The transcranial photobiomodulation will be delivered through the Neuradiant 1070 Plus-Programmable 4-Quadrant Photobiomodulation System. This is a commercially available helmet that will be purchased from a commercially available source.

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus) with no light administered
Description: In this condition the participants will wear the Transcranial Photobiomodulation helmet (Neuradiant 1070 Plus); however, the light will not be administered.
Study: NCT04336111

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: retrolaminar block
Description: will receive real bilateral bilevel ultrasounded guided retrolaminar block at T4 and T10 after induction of anaesthesia in prone position. The total desired volume used in the whole injection will be 40 ml containing 3mg / kg bupivacaine with adrenaline 2.5 2 µg/ml. The total 40 ml volume will be divided into 10 ml for each injection.
Study: NCT05320120

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 56mg esketamine (2x Spravato® 28 mg nasal spray)
Description: 56mg esketamine (2x Spravato® 28 mg nasal spray)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 56mg esketamine (2x Spravato® 28 mg nasal spray)
Description: 56mg esketamine (2x Spravato® 28 mg nasal spray)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution nasal spray
Description: 0.9% saline solution nasal spray

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0.9% saline solution nasal spray
Description: 0.9% saline solution nasal spray
Study: NCT05109156

Intervention type: OTHER
Intervention: This is an observational study
Description: This is an observational study
Study: NCT06060782

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Thiotepa, cyclophosphamide, cladribine, and cytarabine conditioning regimen
Description: All enrolled patients received TCCA conditioning regimen（） before auto-HSCT:~Thiotepa 5mg/kg, -8, -7 days Cyclophosphamide 40mg/kg, -6, -5 days Cladribine 5mg/m2, -4, -3, -2 days Cytarabine 2g/m2, -4, -3, -2 days
Study: NCT05238090

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Passive and active analytical stretching exercises
Description: For each stretching technique described, 3 repetitions of 15 seconds duration will be performed of 15 seconds duration each, within the patient's tolerance threshold. In any case, the impossibility of performing any technique due to exacerbation of pain shall be recorded in a patient record created for this study, noting the technique in question and the reason for its technique in question and the reason for its non-application. Passive stretches shall be applied in the same order for all subjects.~The physiotherapists in charge of applying the treatments will be trained in advance in the different techniques to be applied and will not in the different techniques to be applied and shall not intervene at any time in the two previous phases.~Both the control group and the study group will receive their respective treatments two days a week for four weeks. In no case will any other type of treatment be associated treatment during the whole process.

Intervention type: OTHER
Group type: OTHER
Intervention: Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
Description: Static stretching of the extensor carpi radialis brevis and eccentric strengthening of the wrist extensor musculature
Study: NCT05255536

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plan Block with 20 ml
Description: Superficial serratus anterior plane block with 20 ml will be applied to the patients under real-time ultrasound guidance.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Serratus Anterior Plan Block with 30 ml
Description: Superficial serratus anterior plane block with 30 ml will be applied to the patients under real-time ultrasound guidance.
Study: NCT05432804

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT05494333

Intervention type: OTHER
Intervention: no intervention
Description: NO intervention
Study: NCT05432804

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Selinexor
Description: Given PO

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Temozolomide
Description: Given PO
Study: NCT06021535

Intervention type: OTHER
Intervention: No intervention
Description: No intervention

Intervention type: OTHER
Intervention: No intervention
Description: No intervention
Study: NCT05428410

Intervention type: OTHER
Intervention: IL-4R
Description: IL-4R was injected subcutaneously.

Intervention type: OTHER
Intervention: IL-4R
Description: IL-4R was injected subcutaneously.
Study: NCT05432804

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Given PO
Study: NCT06597175

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ORIGO
Description: The device measurement is first performed on the breast area with the lesion, followed by the measurement of the corresponding area in the contralateral breast for comparison.
Study: NCT05440084

Intervention type: PROCEDURE
Intervention: Chronic total occlusion percutaneous coronary intervention
Description: Chronic total occlusion percutaneous coronary intervention
Study: NCT05572658

Intervention type: BIOLOGICAL
Intervention: mRNA-1345
Description: Sterile liquid for injection

Intervention type: BIOLOGICAL
Intervention: Placebo
Description: 0.9% sodium chloride (normal saline) injection
Study: NCT06538662

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: FID 123320 Ophthalmic Solution
Description: Investigational sterile aqueous solution

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle
Description: FID 123320 Ophthalmic Solution inactive ingredients
Study: NCT06541678

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Danuglipron
Description: MR Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: MR Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Danuglipron
Description: MR Tablet

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclosporine
Description: Capsule

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Itraconazole
Description: Oral solution
Study: NCT06541704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pozelimab
Description: Subcutaneous (SC) injection

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: SC injection
Study: NCT05080504

Intervention type: DEVICE
Intervention: Eko DUO
Description: Each subject will take an Eko DUO device home and take DUO recordings immediately before or after their prescribed CardioMEMS measurements.~The DUO recordings will be taken at 3 predefined chest locations: the right upper sternal border, left upper sternal border, and right anterolateral. Each DUO recording lasts about 15 seconds. The total time per recording session is expected to be 2-4 minutes, which allows for time between recordings and any potential repeat recordings. Study participation will last for 90 days.
Study: NCT05831514

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Mobile Application Supported Education Program (G-MUEP)
Description: Parents who meet the inclusion criteria will use the Mobile Application Supported Education Program (G-MUEP).
Study: NCT05428410

Intervention type: OTHER
Intervention: Placebo
Description: Placebo was injected subcutaneously.
Study: NCT05436717

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MINDxYOU
Description: The online program MINDxYOU is based on the principles of 'third wave' psychotherapies and it is an online program particularly addressed at healthcare providers which will both monitor and support the individual's mental health. The program is self-administered and will be delivered via the Internet and available via smartphone, tablet, and personal computer.
Study: NCT05782127

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Onureg + Venetoclax
Description: Combination of Onureg and Venetoclax
Study: NCT06139029

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 3% normal saline
Description: nebulization

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: steroid(beclomethasone dipropionate 400 μg/day) and salbutamol with 0.9% normal saline
Description: nebulization
Study: NCT06541704

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cemdisiran
Description: SC injection
Study: NCT06506708

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Hydrotherapy + massage
Description: The comprehensive Hammam experience will consist of 3 sessions at the Arab baths of Hammam Al Ándalus, Granada -Spain- (once every two weeks). Each session will involve a thermal circuit lasting approximately 75 minutes, following the institution's guidelines, inviting women to explore the warm, hot, and cold water baths, as well as the steam room. The thermal circuit will be complemented by a 15-minute relaxing massage using essential oils. During the final session, massage will be preceeded by a traditional Kessa treatment on a hot stone bed. During sessions, women will be involved in a multisensory experience, including aromatherapy and where they will also have the opportunity to sipping on mint tea and relax on a building all decorated in resplendent Arabian décor. One member of the research team will be responsible for coordinating the sessions in collaboration with the Al Ándalus institution, subject to their availability.
Study: NCT05799547

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: cold group
Description: Application will be made in the form of 10 minutes of application to the cesarean section incision, 20 minutes of break and 10 minutes of application.
Study: NCT06340373

Intervention type: DEVICE
Intervention: DCB Angioplasty
Description: Drug-coated balloons (DCB) are designed to deliver drugs (antiproliferative drugs: Paclitaxel, Sirolimus etc.) to the target lesion/vessel wall without leaving nothing behind unlike stent strut or drug delivery system. Drug coated balloons (DCB) allow the homogenous transfer of an anti-proliferative drug to reduce neo-intimal hyperplasia whilst maintaining normal vessel anatomy and function